The Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairment
Journal of Alzheimer's Disease · 2024
DOI: 10.3233/jad-230747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, 2024. Verfasst von Yi-Chou Hou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Nephrology, Cardinal Tien Hospital, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, Cognitive Dysfunction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Abstract (Originalsprache)
Background
Cognitive impairment (CI) is one of the major complications in chronic kidney disease patients, especially those with end-stage renal disease (ESRD). Limited biomarkers have been found that can significantly predict ESRD-associated cognitive decline.
Objective
This cohort study aimed to investigate de novo biomarkers for diagnosis of the ESRD-associated CI.
Methods
In this cohort study, qualified samples were divided into control (with an estimated glomerular filtration rate (eGFR) of≥60 mL/min and a Mini-Mental State Examination (MMSE) score of > 27), ESRD without CI (eGFR < 15 and MMSE > 27), and ESRD with CI (eGFR < 15 and MMSE < 27) groups. Levels of plasma amyloid-β (Aβ)1 - 42, serum indoxyl sulfate, and hematologic and biochemical parameters were measured.
Results
Compared to the control group, levels of blood urea nitrogen, creatinine, and indoxyl sulfate were elevated in ESRD patients both without and with CI. Interestingly, ESRD patients with CI had the lowest levels of serum albumin. In contrast, levels of plasma Aβ1 - 42 were significantly higher in the ESRD with CI group than in the control and ESRD without CI groups. In addition, the ratio of plasma Aβ1 - 42 over serum albumin was significantly higher in the ESRD with CI group than in the control or ESRD without CI groups. Importantly, the area under the receiver operating characteristic curve (AUROC) for CI in the total population by the ratio of Aβ1 - 42 over albumin was 0.785 and significant (p < 0.05).
Conclusions
This cohort study has shown that the ratio of plasma Aβ1 - 42 over serum albumin can be a de novo biomarker for the diagnosis and prognosis of ESRD-associated cognitive decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Nephrology, Cardinal Tien Hospital, New Taipei City, Taiwan.
- School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
- Cell Physiology and Molecular Image Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
- Department of Medical Laboratory and Department of Education, Cardinal Tien Hospital, New Taipei City, Taiwan.
- Department of Medicine, Division of Nephrology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
- Department of Neurology, Cardinal Tien Hospital, New Taipei City, Taiwan.
Zitieren
APA
Hou, Y. C., Chueh, T. I., Lu, K. C., Liu, Y. C., Chen, T. H., Liu, S. H., & Chen, R. M. (2024). The Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairment. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-230747
Vancouver
Hou YC, Chueh TI, Lu KC, Liu YC, Chen TH, Liu SH, et al. The Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairment. Journal of Alzheimer's Disease. 2024. doi:10.3233/jad-230747
BibTeX
@article{Hou2024,
author = {Hou, Yi-Chou and Chueh, Ti-I and Lu, Kuo-Cheng and Liu, Yi-Chien and Chen, Tso-Hsiao and Liu, Shing-Hwa and Chen, Ruei-Ming},
title = {The Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairment},
journal = {Journal of Alzheimer's Disease},
year = {2024},
doi = {10.3233/jad-230747}
}
EUVIMED